Opiant Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, May 9

SANTA MONICA, Calif., April 30, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") OPNT, a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it will report its financial results for the first quarter ended March 31, 2019, after the market close, and will host a corporate update conference call and webcast on Thursday, May 9, at 4:30 p.m. Eastern Time.

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing medicines for addictions and drug overdose. The National Institute on Drug Abuse, a division of NIH, describes addictive disorders as chronic relapsing brain diseases that burden society at both the individual and community levels. Opiant's first drug overdose product, NARCAN^® Nasal Spray, is licensed to Adapt Pharmaceuticals, now owned by Emergent BioSolutions, Inc. For more information, visit www.opiant.com.

CONTACTS:
For Media Inquiries:
Julie Normart, W2O Group
(415) 946-1087
jnormart@w2ogroup.com

For Investor Inquiries:
Dan Ferry, LifeSci Advisors, LLC
(617) 535-7746
Daniel@lifesciadvisors.com